Creating strong bonds through a range of leading vaccines. 1. Gray A et al (2003) Nobivac ® DHPPi offers protection against infection with CDV and CPV within 7 days of vaccination. Proceedings 46th BSAVA Annual Congress, Birmingham, UK, 3-6 April 2003: p. 559. 2. Helps J et al (2007) An injectable modified live vaccine protects young puppies against challenge with either canine adenovirus-1 or canine adenovirus-2 seven days after a single vaccination. Proceedings 40th Voorjaarsdagen congress, 27th-29th April 2007, Amsterdam, NL: p. 193. 3. Hoskins JD et al (1995) Challenge Trial of a New Attenuated Canine Parvovirus Vaccine. Journal of Veterinary Internal Medicine 9:197. 4. Greenwood NM et al (1995) Comparison of isolates of canine parvovirus by restriction enzyme analysis, and vaccine efficacy against field strains. Veterinary Record 136: 63-67. 5. Horspool LJI et al (2005) A MLV vaccine pre- vents clinical signs and shedding of CPV type 2a and 2b after challenge at 36 months after vaccination. Proceedings 48th BSAVA Annual References Distemper (MLV) Parvovirus (MLV) Adenovirus type 2 (MLV) Parainfluenza (MLV) Bordetella (Modified-live) Parainfluenza (Inactivated) Bordetella (Inactivated) Vaccine Presentation Nobivac DHP ••• 10 or 20 doses Nobivac DHPPi •••• 10 doses Nobivac KC (Intranasal) •• 5 or 10 doses (with diluents) Nobivac Bb/Pi •• 20 doses Nobivac Puppy Pack 20 doses Nobivac DHP + 10 doses (with diluents) Nobivac KC Nobivac C5 Pack 20 doses Nobivac DHP + 20 doses Nobivac Bb/Pi The Nobivac Canine Vaccine range comprises vaccines and services that reflect MSD Animal Health’s long experience and leadership in small animal vaccine development. A strong research commitment to small animal vaccines ensures that the Nobivac vaccines are of the highest quality, trusted for their efficacy and safety. The Nobivac range is manufactured locally in Bendigo, Victoria, and is supplied in recyclable packaging. Canine Vaccines SO936 congress, 7th-10th April 2005, Birmingham, UK: pp. 548. 6. Spibey N et al (2007) Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Veterinary Microbiology 128: 48-55. 7. Bergman JGJE et al (2005) A MLV vac- cine has a duration of immunity of at least 36 months against CDV, CAV2 and CPV. Proceedings 48th BSAVA Annual congress, 7th-10th April 2005, Birmingham, UK: pp. 54. 8. Gore T et al (2005) Three-Year Duration of Immunity in dogs following vaccination against Canine Adenovirus Type-1, Canine Parvovirus, and Canine Distemper Virus. Veterinary Therapeutics Vol.6, No.1, Spring 2005: 5-14. 9. Gore T et al (2005) Intranasal kennel cough vaccine protecting dogs from experimental Bordetella bronchiseptica challenge within 72 hours. Veterinary Record 156:482-483. 10. Jacobs AA et al (2005) Protection of dogs for 13 months against Bordetella bronchiseptica and canine parainfluenza virus with a modified live vaccine. Veterinary Record 157:19-23. 11. Edinboro CH et al (2004) A placebo-controlled trial of two intranasal vaccines to prevent tra- cheobronchitis (kennel cough) in dogs entering a human shelter. Preventive Veterinary Medicine 62: 89-99. 12. Jacobs AAC et al (2006) An intranasal kennel cough vaccine administered at 3 weeks of age is able to stimulate protective immunity despite the presence of passive antibody. Proceedings 31st WSAVA Congress 11th - 14th October 2006, Prague: p. 850. 13. Data on file: Antibody, challenge and safety studies (Registration dossier, Part III, pages 22-83). 14. Bergman JGHE et al (2006) Comparative trial of the canine parvovirus, canine distemper virus and canine adenovirus type 2 fractions of two commercially available modified live vaccines. Veterinary Record 159: 733-736. MSD Animal Health 91-105 Harpin Street, Bendigo East VIC 3550 Free Call: 1800 033 461 www.msd-animal-health.com.au
2
Embed
Canine Vaccines - · PDF fileCanine Vaccines SO936 congress, 7th-10th April 2005, Birmingham, UK: pp. 548. 6. Spibey N et al (2007) Canine parvovirus type 2 vaccine protects against
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Creating strong bonds through a range of leading vaccines.
1. Gray A et al (2003) Nobivac® DHPPi offers protection against infection with CDV and CPV within 7 days of vaccination. Proceedings 46th BSAVA Annual Congress, Birmingham, UK, 3-6 April 2003: p. 559.
2. Helps J et al (2007) An injectable modified live vaccine protects young puppies against challenge with either canine adenovirus-1 or canine adenovirus-2 seven days after a single vaccination. Proceedings 40th Voorjaarsdagen congress, 27th-29th April 2007, Amsterdam, NL: p. 193.
3. Hoskins JD et al (1995) Challenge Trial of a New Attenuated Canine Parvovirus Vaccine. Journal of Veterinary Internal Medicine 9:197.
4. Greenwood NM et al (1995) Comparison of isolates of canine parvovirus by restriction enzyme analysis, and vaccine efficacy against field strains. Veterinary Record 136: 63-67.
5. Horspool LJI et al (2005) A MLV vaccine pre-vents clinical signs and shedding of CPV type 2a and 2b after challenge at 36 months after vaccination. Proceedings 48th BSAVA Annual
A strong research commitment to small animal vaccines
ensures that the Nobivac vaccines are of the highest
quality, trusted for their efficacy and safety.
The Nobivac range is manufactured locally in Bendigo,
Victoria, and is supplied in recyclable packaging.
Canine Vaccines
SO93
6
congress, 7th-10th April 2005, Birmingham, UK: pp. 548.
6. Spibey N et al (2007) Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Veterinary Microbiology 128: 48-55.
7. Bergman JGJE et al (2005) A MLV vac-cine has a duration of immunity of at least 36 months against CDV, CAV2 and CPV. Proceedings 48th BSAVA Annual congress, 7th-10th April 2005, Birmingham, UK: pp. 54.
8. Gore T et al (2005) Three-Year Duration of Immunity in dogs following vaccination against Canine Adenovirus Type-1, Canine Parvovirus, and Canine Distemper Virus. Veterinary Therapeutics Vol.6, No.1, Spring 2005: 5-14.
9. Gore T et al (2005) Intranasal kennel cough vaccine protecting dogs from experimental Bordetella bronchiseptica challenge within 72 hours. Veterinary Record 156:482-483.
10. Jacobs AA et al (2005) Protection of dogs for
13 months against Bordetella bronchiseptica and canine parainfluenza virus with a modified live vaccine. Veterinary Record 157:19-23.
11. Edinboro CH et al (2004) A placebo-controlled trial of two intranasal vaccines to prevent tra-cheobronchitis (kennel cough) in dogs entering a human shelter. Preventive Veterinary Medicine 62: 89-99.
12. Jacobs AAC et al (2006) An intranasal kennel cough vaccine administered at 3 weeks of age is able to stimulate protective immunity despite the presence of passive antibody. Proceedings 31st WSAVA Congress 11th - 14th October 2006, Prague: p. 850.
13. Data on file: Antibody, challenge and safety studies (Registration dossier, Part III, pages 22-83).
14. Bergman JGHE et al (2006) Comparative trial of the canine parvovirus, canine distemper virus and canine adenovirus type 2 fractions of two commercially available modified live vaccines. Veterinary Record 159: 733-736.
MSD Animal Health 91-105 Harpin Street, Bendigo East VIC 3550
Provides convenience of administration for fractious dogs
Challenge trial demonstrated significant protection against Bb and CPi13
Can be used as a diluent to reconstitute Nobivac DHP to permit administration of a single ‘C5’ vaccination
Technical ServicesExperienced veterinarians are available to provide technical support for your practice for Intervet/Schering-Plough’s extensive product range.
✆ 1800 033 461Call to speak to one of our Technical Services Veterinarians
Services and advice include:• Vaccinationprotocols• Questionsrelabelclaims• Monitoringofpost-registrationproductperformance• Productcomplaintinvestigations
PREMIUMParvo
Protection
Nobivac KC Nobivac Bb/Pi
INTRANASALCanine Cough VACCINE
INJECTABLECanine Cough Vaccine
VACCINATIoN PRogRAM foR NoBIVAC KC
Primary vaccination in dogs A single dose of Nobivac KC administered to dogs ≥ 4 weeks of age
Annual revaccination is recommended
VACCINATIoN PRogRAM foR NoBIVAC Bb/Pi
Primary vaccination in dogs 2 doses of Nobivac Bb/Pi at an interval of one month to dogs ≥ 6 weeks of age
Annual revaccination is recommended
Cross-protection: Clinical signs following CPV-2, CPV-2a and CPV-2b challenge3
100%
80%
60%
40%
20%
0%
Contr
ol
Vacci
nates
3 years duration of immunity: Clinical signs following CDV, CAV-1 and CPV challenge 3 years after vaccination with Nobivac DHP8
100%
80%
60%
40%
20%
0%
CDV
Vacci
nates
CAV-1
Vacci
nates
CPV
Vacci
nates
Contr
ol
Contr
ol
Contr
ol
Duration of immunity: Mean clinical scores after combined challenge with Bordetella bronchiseptica and canine parainfluenza virus carried out 56 weeks after vaccination10
10
5
0
15
Vacci
nates
Cont
rol
Onset of immunity: Mean clinical scores after Bordetella bronchiseptica challenge, carried out 72 hours after vaccination9
10
8
6
4
2
0
12
14
16
18
Vacci
nates
Cont
rol
10 week finish: Serological response to vaccination14
6 week vaccination
100%
80%
60%
40%
20%
0%10 week vaccination
n CDV n CAV-2 n CPV
VACCINATIoN PRogRAM foR NoBIVAC DHP/DHPPi
Puppies Where vaccination commences at 6 - 8 weeks of age: 1st dose 6 - 8 weeks: Nobivac DHP (or DHPPi)2nd dose 10 weeks: Nobivac DHP (or DHPPi)Where vaccination commences at ≥ 10 weeks of age: Single dose of Nobivac DHP (or DHPPi)
1st booster: 12 months after primary vaccinationSubsequent boosters: Every 3 years for distemper, hepatitis and parvovirus
Adult Dogs A single vaccination with Nobivac DHP or DHPPi will provide at least 3 years protection against distemper, hepatitis and parvovirus
Booster vaccination: Every 3 years for distemper, hepatitis and parvovirus